Anthony Mills
About
Anthony Mills is a scholar working on Infectious Diseases, Virology and Emergency Medicine.
According to data from OpenAlex, Anthony Mills has authored 63 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Infectious Diseases, 46 papers in Virology and 13 papers in Emergency Medicine. Recurrent topics in Anthony Mills's work include HIV/AIDS drug development and treatment (54 papers), HIV Research and Treatment (46 papers) and HIV/AIDS Research and Interventions (28 papers). Anthony Mills is often cited by papers focused on HIV/AIDS drug development and treatment (54 papers), HIV Research and Treatment (46 papers) and HIV/AIDS Research and Interventions (28 papers). Anthony Mills collaborates with scholars based in United States, United Kingdom and France. Anthony Mills's co-authors include Andrew Cheng, Kirsten White, Beatriz Grinsztejn, Joel E. Gallant, Pedro Cahn, Erin Quirk, Edwin DeJesus, Jean‐Michel Molina, David A. Wohl and Adriano Lazzarin and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Clinical Infectious Diseases.
In The Last Decade
Anthony Mills
63 papers receiving 3.0k citations
Hit Papers
Peers
Anthony Mills
Franco Maggiolo Italy
Erin Quirk United States
Marshall W. Fordyce United States
Benoît Trottier Canada
Isabelle Pellegrin France
Javier O Morales-Ramirez United States
Susan L. Ford United States
Brian Wynhoven Canada
Hans-Jürgen Stellbrink Germany
Markus Bickel Germany
Citations per year, relative to Anthony Mills Anthony Mills (= 1×)
peers
Franco Maggiolo
Countries citing papers authored by Anthony Mills
Since
Specialization
Citations
This map shows the geographic impact of Anthony Mills's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony Mills with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony Mills more than expected).
Fields of papers citing papers by Anthony Mills
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Anthony Mills. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony Mills. The network helps show where Anthony Mills may publish in the future.
Co-authorship network of co-authors of Anthony Mills
This figure shows the co-authorship network connecting the top 25 collaborators of Anthony Mills. A scholar is included among the top collaborators of Anthony Mills based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony Mills. Anthony Mills is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Colson, Amy E., Anthony Mills, Christopher Bettacchi, et al.. (2026). Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial. The Lancet. 407(10528). 611–621.
2.
Pierone, Gerald, Jennifer S Fusco, Laurence Brunet, et al.. (2024). Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States. AIDS Research and Therapy. 21(1). 76–76.
3.
Mills, Anthony, Kathy L. Schulman, Jennifer S Fusco, et al.. (2021). Virologic Outcomes Among People Living With Human Immunodeficiency Virus With High Pretherapy Viral Load Burden Initiating on Common Core Agents. Open Forum Infectious Diseases. 8(8). ofab363–ofab363.
4.
Brar, Indira, Peter Ruane, Douglas Ward, et al.. (2020). 1028. Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine. Open Forum Infectious Diseases. 7(Supplement_1). S543–S544.
5.
Sax, Paul E., Edwin DeJesus, Gordon Crofoot, et al.. (2018). Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide. AIDS. 32(12). 1723–1725.
6.
DeJesus, Edwin, Sorana Segal‐Maurer, Moti Ramgopal, et al.. (2018). Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment. AIDS Research and Human Retroviruses. 34(4). 337–342.
7.
DeJesus, Edwin, Moti Ramgopal, Gordon Crofoot, et al.. (2017). Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. The Lancet HIV. 4(5). e205–e213.
8.
Gallant, Joel E., Adriano Lazzarin, Anthony Mills, et al.. (2017). Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. The Lancet. 390(10107). 2063–2072.
9.
Lackey, Philip, Anthony Mills, Félix Carpio, et al.. (2016). Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice. Clinical Drug Investigation. 37(1). 51–60.
10.
Mills, Anthony, Will Garner, Anton Pozniak, et al.. (2015). Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF. Patient. 8(4). 359–371.
11.
Mills, Anthony, Gordon Crofoot, Cheryl McDonald, et al.. (2015). Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 69(4). 439–445.
12.
Behrens, Georg M. N., Bart Rijnders, Mark Nelson, et al.. (2014). Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis. AIDS Patient Care and STDs. 28(4). 168–175.
13.
Nelson, Mark, Richard Elion, C Cohen, et al.. (2013). Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies. HIV Clinical Trials. 14(3). 81–91.
14.
Mills, Anthony, Calvin Cohen, Edwin DeJesus, et al.. (2013). Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens. HIV Clinical Trials. 14(5). 216–223.
15.
Sax, Paul E., Edwin DeJesus, Anthony Mills, et al.. (2012). Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. The Lancet. 379(9835). 2439–2448.
16.
DeJesus, E, et al.. (2011). A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients. International Journal of Clinical Practice. 65(12). 1240–1249.
17.
Yéni, Patrick, Anthony Mills, Monika Peeters, et al.. (2010). Etravirine in the Treatment of HIV-1: A Clinical Overview for Healthcare Professionals. Current HIV Research. 8(7). 564–576.
18.
Mills, Anthony. (2008). ARTEMIS: Efficacy and Safety of Darunavir/ritonavir (DRV/r) 800/100 mg Once-daily vs Lopinavir/ritonavir (LPV/r) in Treatment-naïve, HIV-1-infected Patients at 96 Wks. 46th Annual Meeting.
19.
Madruga, José Valdez, Pedro Cahn, Beatriz Grinsztejn, et al.. (2007). Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. The Lancet. 370(9581). 29–38.
20.
Ryan, Travis J., et al.. (2000). Seminatrix pygaea . Diet.. Herpetological review. 31. 47–47.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Franco Maggiolo Breakdown of academic impact, for papers by Erin Quirk Breakdown of academic impact, for papers by Marshall W. Fordyce Breakdown of academic impact, for papers by Benoît Trottier Breakdown of academic impact, for papers by Isabelle Pellegrin Breakdown of academic impact, for papers by Javier O Morales-Ramirez Breakdown of academic impact, for papers by Susan L. Ford Breakdown of academic impact, for papers by Brian Wynhoven Breakdown of academic impact, for papers by Hans-Jürgen Stellbrink Breakdown of academic impact, for papers by Markus Bickel